Skip to content

Internet Buzzes About Today’s (October 11, 2012) Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) And VX-809 Phase II Results

October 11, 2012

       The Internet buzzes on October 11, 2012 about Vertex Pharmaceuticals’ orphan drug VX-809 + Kalydeco (Ivacaftor) Phase II study results : 

1) October 11, 2012 1:54 PM article titled,”The Best Argument That Vertex’s CF Drug Combination Works” :

                   –      Raises the question “whether this combination (VX-809 + Kalydeco) is working or whether what looks like efficacy is just noise …” 

2) October 11, 2012 3:29 PM article titled,”Independent Expert Likes Vertex CF Data” :

–          The combination of the unapproved VX-809 pill + orphan drug Kalydeco, “could help 50% of CF patients – up from the 4% that can be helped by Kalydeco alone. That’s another 15,000 Americans who will literally be able to breathe easier ….. “

–          Independent expert said data is “very exciting” but it is “confusing that the amount of chloride in patients sweat, a marker for CF severity, did not differ between patients on the drug & those on the placebo …….”

–          Kalydeco costs $294,000/patient/year

–          No information on cost of VX-809 + Kalydeco combination. 

3) October 11, 2012 article titled,”Vertex’s new data on CF drug cocktail doesn’t disappoint”  

4) October 11, 2012 article titled,”Vertex Cystic Fibrosis Combo Therapy Passes Key Confidence Test”.   

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: